List view / Grid view
Three-dimensional (3D) models are reshaping pre-clinical drug development by providing more accurate insights into drug safety and efficacy. Explore how these advanced in vitro systems help improve predictions and reduce the risk of failure in early-stage drug discovery.
Researchers have developed a test that accurately predicts whether patients with ALK-positive lung cancer will respond to targeted treatments. This could significantly enhance personalised cancer therapies and overcome treatment resistance.
Tubulis, led by CEO Dominik Schumacher, is advancing cancer treatment through next-generation antibody-drug conjugates (ADCs) designed to target solid tumours more effectively. Find out how the company is rapidly progressing its ADC pipeline to offer more precise and lasting treatment options for patients.
Learn how to simplify the entire DNA template generation workflow, streamlining mRNA therapeutic research.
Deep learning is transforming lung disease treatment by enabling earlier diagnosis, precise monitoring and more efficient clinical trials. This article explores how AI-driven imaging is accelerating drug development and improving patient outcomes.
In this first interview of a two-part series, Andreas Kolleger explores the convergence of knowledge graphs and large language models. As the head of GenAI innovation at Neo4j, Andreas brings a unique cross-industry perspective on how these technologies can enhance life sciences workflows.
Find out how LB Pharmaceuticals' LB-102 is advancing schizophrenia treatment. This first-in-class antipsychotic demonstrates strong efficacy, safety and tolerability, potentially addressing both acute and negative symptoms. Explore its potential impact on neuropsychiatric drug discovery.
A team of scientists from the University of Birmingham has discovered a powerful new treatment for psoriasis. The treatment uses a tripeptide that has shown steroid-level effectiveness in reducing symptoms, offering fresh hope for the long-term management of this chronic skin condition.
Rutgers researchers have discovered new insights into how polycystic kidney disease (PKD) progresses, which could lead to more targeted treatments. This breakthrough may help improve therapies for PKD patients in the future.
14 April 2025 | By Drug Target Review
Our editorial webinars provide free access to content from subject matter experts and leading scientists, making them a valuable resource in the field of cancer research. These webinars help generate hundreds of leads by offering an easy way to engage your target audience. As a sponsor, you’ll gain full access…
ELRIG, a UK-based scientific community driving innovation in drug discovery, has appointed biopharma leader Dr Del Trezise as its new Chair - signalling a bold new chapter for the organisation.
From law to biotech, Brian Finrow's career path has been anything but conventional. As Co-founder and CEO of Lumen Bioscience, he’s steering the company’s innovative approach to drug discovery, focusing on preventative biologics that offer scalable, cost-effective solutions. Find out how Finrow's unique spirulina-based platform is changing the way we…
What if vaccines could train your immune system to eliminate infections at the source? Find out how Gylden Pharma’s gold nanoparticle platform delivers targeted T cell immunity - providing a precise and durable defence against complex infectious diseases.
Dr Cyril Clarke at ICON Biotech reveals how biomarkers are transforming early-phase clinical trials by offering valuable insights into the safety and efficacy of novel therapies.
GPCRs are crucial drug targets, but their complex structures present significant challenges in drug discovery. In this article, Domainex’s Philip Rawlins explores how fragment-based screening and innovative technologies like PoLiPa are helping to overcome these hurdles, with a focus on the Adenosine A2a receptor.
